Gilead Sciences Inc (GILD)

NASDAQ
Currency in USD
Disclaimer
77.09
-0.56
(-0.72%)
Closed
77.20
+0.11
(+0.14%)
After Hours
Real-time Data
Day's Range
77.01
78.62
52 wk Range
57.17
89.74
Volume
5,351,944
Prev. Close
77.65
Open
78
Day's Range
77.01-78.62
52 wk Range
57.17-89.74
Volume
5,351,944
Average Volume (3m)
5,289,089
1-Year Change
18.97%
Shares Outstanding
1,247,352,689
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
91.61
Upside +18.83%

People Also Watch

216.93
AMGN
-0.24%
812.73
AVGO
+11.52%
39.48
CMCSA
+1.00%
224.15
FDX
-0.41%

Gilead Sciences Inc News

Gilead Sciences Inc Analysis

Gilead Sciences Inc Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Stribild. The Company’s COVID-19 product is Veklury. The Company’s also provides Epclusa, Harvoni, Vemlidy, and Viread products for liver diseases. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The Company’s other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Employees
14400